Biocon opens higher as Citi maintains buy rating

Shares of Biocon climbed over 1 percent in early trade after Citi retained its buy rating on the stock with a target price of Rs 800 per share.

The biosimilars business is at an inflection point, the financial service company said in its research note.

Citi added that Biocon is one of its top picks. Risk-reward ratio is favourable at current levels.